APG Asset Management N.V. Sells 1,033,141 Shares of Pfizer Inc. $PFE

APG Asset Management N.V. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 22.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,501,524 shares of the biopharmaceutical company’s stock after selling 1,033,141 shares during the period. APG Asset Management N.V. owned about 0.06% of Pfizer worth $89,219,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after acquiring an additional 1,820,634 shares during the last quarter. Norges Bank bought a new position in shares of Pfizer during the second quarter valued at $2,270,157,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC grew its stake in shares of Pfizer by 2.0% in the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after purchasing an additional 950,239 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on PFE shares. Citigroup initiated coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Bank of America lowered their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Finally, Scotiabank initiated coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $27.70.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Pfizer Trading Up 1.9%

PFE opened at $27.61 on Friday. The company has a fifty day moving average price of $26.13 and a two-hundred day moving average price of $25.41. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a market cap of $156.97 billion, a P/E ratio of 20.30 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the business posted $0.63 EPS. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.